UNBELIEVABLE - CLONED PIGS PRODUCED!

LONDON (AFX) - PPL Therapeutics PLC, the biopharmaceutical group that
specialises in developing treatments from cloning technology, said it has
produced cloned pigs suitable for human transplant use.
The company said it has produced "knock-out" piglets born as a result of
cloning and PPL's patented gene targeting technology. A "knock-out" pig has the
specific gene that leads to the human immune system rejecting pig organs
inactivated.
It said, "in future, this vital step should enable organs and/or cells from
such animals to be transplanted into humans and not be rejected by the human
recipient."
PPL Therapeutics also said it is looking for a spin-out partner to take
forward the areas of so-called "xenotransplantation" and stem cell research, as
its financial resources are being focused on bringing its lead product recAAT,
for treating hereditary emphysema, to the market as quickly as possible.